Risk factor
Very poor trading liquidity
Profitability factor
Very low or no dividends
About
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid isolation, NA and PCR electrophoresis, protein electrophoresis, enzymes, antibiotics, agaroses and molecular biology media, media and buffers for in vitro cultures, phenotypic micromatrices, plastics and small equipment, basic substrate components, and form. In addition, it offers laboratory diagnostics solutions for various areas of clinical chemistry, haematology, coagulology, immunochemistry, POCT, rapid tests, and blood collection systems; and disposable materials comprising microbiology, dispensing equipment, tubes, plugs, tripods, capillaries, equipment, aspiration-vacuum system, containers, tank for analysers, urine analysis, microscope slides, reagent tubes, autoclave equipment, and pliers and scissors. BioMaxima S.A. was founded in 1997 and is headquartered in Lublin, Poland.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral o